Table of Contents
- What is MK-1088?
- What condition does MK-1088 treat?
- How is MK-1088 administered?
- Current Clinical Trial
- Combination Therapy with Pembrolizumab
- Safety and Side Effects
- Effectiveness of MK-1088
What is MK-1088?
MK-1088 is a new drug being studied for the treatment of advanced solid tumors. It is currently undergoing clinical trials to evaluate its safety, effectiveness, and how it works in the body (known as pharmacokinetics)[1]. MK-1088 is an oral medication, which means it’s taken by mouth in the form of a tablet[1].
What condition does MK-1088 treat?
MK-1088 is being developed to treat advanced solid tumors[1]. Solid tumors are abnormal masses of tissue that don’t contain cysts or liquid areas. They can occur in many parts of the body, such as the lungs, breast, colon, or prostate. When a solid tumor is described as “advanced,” it typically means that the cancer has spread from where it started to other parts of the body or is at a later stage that’s more difficult to treat.
This drug is being studied in patients whose tumors have not responded to conventional therapy, which means standard treatments haven’t been effective in controlling their cancer[1].
How is MK-1088 administered?
MK-1088 is given as an oral tablet that patients take daily. In the current clinical trial, different dosages are being tested[1]:
- 100 mg daily
- 200 mg daily
- 400 mg daily
- 600 mg daily
The medication is taken on days 1-21 of each 21-day cycle. This means patients take the drug for 21 days, followed by a 7-day break before starting the next cycle. The treatment can continue for up to 35 cycles, which is approximately 24 months (2 years)[1].
Current Clinical Trial
MK-1088 is currently being studied in a Phase 1/Phase 2 clinical trial. This type of trial is designed to[1]:
- Evaluate the safety and tolerability of the drug
- Determine how the drug behaves in the body (pharmacokinetics)
- Examine the effect of MK-1088 on tumor size
The trial is testing MK-1088 both as a single treatment (monotherapy) and in combination with another drug called pembrolizumab[1].
Combination Therapy with Pembrolizumab
In addition to testing MK-1088 alone, the clinical trial is also studying how it works when combined with a drug called pembrolizumab. Pembrolizumab is an immunotherapy drug that helps the immune system fight cancer cells[1].
In the combination therapy part of the trial:
- Patients receive MK-1088 daily (either 100 mg or 200 mg) on days 1-21 of each 21-day cycle
- They also receive pembrolizumab as an intravenous (IV) infusion of 200 mg every 3 weeks, on day 1 of each 21-day cycle
- This combination treatment can continue for up to 35 cycles (approximately 24 months)[1]
Safety and Side Effects
A major focus of the clinical trial is to assess the safety of MK-1088. The researchers are particularly interested in[1]:
- Dose-limiting toxicities (DLTs): These are side effects severe enough to prevent increasing the dose of the drug.
- Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the treatment, whether or not it’s considered related to the drug.
- The percentage of participants who have to stop treatment due to side effects.
The trial is closely monitoring these aspects to ensure patient safety and to determine the most appropriate dose for future use[1].
Effectiveness of MK-1088
To measure how well MK-1088 works, the researchers are looking at the Objective Response Rate (ORR). This measures the percentage of patients whose tumors shrink or disappear after treatment. The ORR includes two types of responses[1]:
- Complete Response (CR): All detectable signs of the tumor disappear
- Partial Response (PR): The tumor shrinks by at least 30%
These responses are assessed using standardized criteria called RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) or a modified version for prostate cancer. The effectiveness is being evaluated for both MK-1088 alone and in combination with pembrolizumab[1].
